Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by wexworthon Oct 14, 2020 2:39pm
157 Views
Post# 31715115

RE:RE:Who is behind the curtain?

RE:RE:Who is behind the curtain?I am just glad that they were able to say that they were dealing with a large pharma in the top 10. The fact that they are not disclosed at this point should speak to the degree of hyper competition in this space. I suspect Sirona had no choice on this. We just added another major global partner to the growing portfolio. When the partner is ready to be revealed, they will make that happen. They are driving the clinical bus right now and that is a much different situation than what we would have faced six or twelve months ago with a new partner. I suspect that at some point, this other mysterious partner on sglt2 (pets or something else?) will reveal itself, and if so, that could produce a stronger reaction that we are all looking for. I am very pleased with the fact that the very big industry players are interested and engaged in the Sirona science platform. This should speak volumes to smart investors.
Bullboard Posts